Several investigations have indicated that the expression levels of Siglec-1, CD22, and Siglec-14 are significantly reduced in AML patients with FLT3 mutations, while the levels of CD33 and Siglec-15 are markedly increased (96). The gene discussed is CD33; the disease is acute myeloid leukemia.